Literature DB >> 7640497

[Clinical research of compound salviae miltiorrhizae injection for severe pancreatitis].

M Xie1, Z Y Jin, G H Ye.   

Abstract

Compound salviae miltiorrhizae injection was administered after operation for 28 cases of severe pancreatitis, and 13 cases were taken as a control group. The results showed that: (1) the difference was not obvious in the morbidity of complications between the two groups, but the mortality (3.6%) of the trial group was significantly lower than that (30.8%) of the control group (P < 0.05); (2) Hematocrit was clearly decreased from 46.1 +/- 5.2% to 33.2 +/- 3.9% in the trial one (P < 0.05), but platelet and hemoglobin showed no statistical significance. It is concluded that compound salviae miltiorrhiza injection might improve hemorheologic abnormalities of the disease, promote the recovery of the pancreatic tissue, and correct the serious complications such as adult respiratory distress syndrome etc.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640497

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  3 in total

1.  Effect of salvia miltiorrhizae on the expressions of TLR4 protein in the liver of rats with SAP or OJ.

Authors:  Xiping Zhang; Daren Liu; Dijiong Wu; Chongmei Zhu; Jing Ye; Keyi Wang; Liang Peng; Guangchao Zhuo
Journal:  Inflammation       Date:  2009-06       Impact factor: 4.092

2.  Efficacy and mechanism of Salvia miltiorrhizae injection in the treatment of rats with severe acute pancreatitis.

Authors:  Ruiping Zhang; Xiping Zhang; Jie Zhang; Junsheng Wu; Qian Ye; Rujun Xu; Jing Ye; Xin Fang; Lu Jin; Jiao He; Wenqin Yuan
Journal:  Inflammation       Date:  2009-04       Impact factor: 4.092

3.  Tanshinone IIA Protects against Acute Pancreatitis in Mice by Inhibiting Oxidative Stress via the Nrf2/ROS Pathway.

Authors:  Weiwei Chen; Chenchen Yuan; Yingying Lu; Qingtian Zhu; Xiaojie Ma; Weiming Xiao; Weijuan Gong; Wei Huang; Qing Xia; Guotao Lu; Weiqin Li
Journal:  Oxid Med Cell Longev       Date:  2020-04-08       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.